AboutONCOMATRYX BIOPHARMA SL
Our mission, to target the tumor stroma to create new personalized drugs and diagnostic products for the treatment of cancer.
Oncomatryx Biopharma has developed a comprehensive portfolio of antibody-drug conjugates, immunotoxins, and human-derived proteins that target tumor-associated stroma.
The peritumoral stroma is a complex and heterogeneous network of cellular components - fibroblasts, endothelial cells and non-cellular - extracellular matrix, which play a very important role in growth, invasion, vascularization, metastasis and resistance to penetration of tumor pharmaceutical treatment.
Oncomatryx Biopharma has also developed companion diagnostic products that are used to diagnose and predict tumor invasiveness, as well as select and monitor patients who are likely to receive Oncomatryx immunoconjugates from the clinical trial stage.
Stromal tumor targeting
The therapeutic approach of Oncomatryx is based on the development of new personalized biological drugs, directed against targets located in the peritumoral stroma, a new and innovative way of treating cancer, aimed at attacking not the tumor cells, but the cells that facilitate invasiveness and tumor resistance.
Oncomatryx has been actively developing and licensing therapeutic human antibodies, immunotoxins, immunodrugs/antibody-drug conjugates, and proteins, which will be validated as personalized biologics to treat invasive carcinomas.